Aggregation of antigen-specific T cells at the inoculation site of mature dendritic cells.

Cellular immune responses are initiated by direct interaction of naive T cells with professional antigen-presenting cells, i.e., dendritic cells. In general, this interaction takes place in secondary lymphoid organs to which both naive T cells and mature dendritic cells preferentially home. This physiologic scenario differs substantially, however, from therapeutic dendritic-cell-based vaccinations used to treat human cancer. In fact, only a small fraction of intradermally injected dendritic cells migrate to the draining lymph node and the majority of cells remain at the site of inoculation. These sites are characterized by a distinct oligoclonal T cell infiltrate comprising both L-Selectin+/CD45RA+ and L-Selectin+/CD45RA- cells. Blood vessels expressing peripheral lymph node addressin represent possible entry channels for such naive and central memory T cells, the former probably attracted by dendritic cell-CK1 produced by the injected dendritic cells. In situ staining with multimeric peptide/major histocompatibility complex class I complexes revealed that infiltrating T cells specifically recognize peptide epitopes presented by the injected dendritic cells. Thus, the fraction of dendritic cells not migrating to secondary lymphatic tissue after therapeutic inoculation nevertheless seem to be involved in a specific immune modulation.

[1]  J. Becker,et al.  Induction of systemic CTL responses in melanoma patients by dendritic cell vaccination: Cessation of CTL responses is associated with disease progression , 2001, International journal of cancer.

[2]  J. Becker,et al.  Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. , 2001, Cancer research.

[3]  Stephen P. Schoenberger,et al.  Naïve CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation , 2001, Nature Immunology.

[4]  D. Speiser,et al.  Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  J. Becker,et al.  Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue. , 2001, Immunity.

[6]  K. Matsushima,et al.  Identification of genes specifically expressed in human activated and mature dendritic cells through serial analysis of gene expression. , 2000, Blood.

[7]  A. Enk,et al.  Mage-3 and Influenza-Matrix Peptide-Specific Cytotoxic T Cells Are Inducible in Terminal Stage HLA-A2.1+ Melanoma Patients by Mature Monocyte-Derived Dendritic Cells1 , 2000, The Journal of Immunology.

[8]  T. Schumacher,et al.  In situ detection of virus- and tumor-specific T-cell immunity , 2000, Nature Medicine.

[9]  E. Bröcker,et al.  Antigen presentation in extracellular matrix: interactions of T cells with dendritic cells are dynamic, short lived, and sequential. , 2000, Immunity.

[10]  A. Haase,et al.  Cutting Edge: In Situ Tetramer Staining of Antigen-Specific T Cells in Tissues1 , 2000, The Journal of Immunology.

[11]  U. V. von Andrian,et al.  The Cc Chemokine Thymus-Derived Chemotactic Agent 4 (Tca-4, Secondary Lymphoid Tissue Chemokine, 6ckine, Exodus-2) Triggers Lymphocyte Function–Associated Antigen 1–Mediated Arrest of Rolling T Lymphocytes in Peripheral Lymph Node High Endothelial Venules , 2000, The Journal of experimental medicine.

[12]  A. Enk,et al.  Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma , 1999, The Journal of experimental medicine.

[13]  Simon,et al.  Analysis of mouse dendritic cell migration in vivo upon subcutaneous and intravenous injection , 1999, Immunology.

[14]  W. Oyen,et al.  Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. , 1999, Cancer research.

[15]  F. Sallusto,et al.  Mobilizing Dendritic Cells for Tolerance, Priming, and Chronic Inflammation , 1999, The Journal of experimental medicine.

[16]  A. Sette,et al.  HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients. , 1998, Journal of immunology.

[17]  S. Rosenberg,et al.  Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. , 1998, The cancer journal from Scientific American.

[18]  P. Guldberg,et al.  Detection and Characterization of αβ-T-Cell Clonality by Denaturing Gradient Gel Electrophoresis (DGGE) , 1998 .

[19]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[20]  Dirk Schadendorf,et al.  Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.

[21]  P. Romero,et al.  Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. , 1998, Journal of immunology.

[22]  J. Altman,et al.  Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. , 1998, Immunity.

[23]  T. Mcclanahan,et al.  A dendritic-cell-derived C–C chemokine that preferentially attracts naive T cells , 1997, Nature.

[24]  P. Romero,et al.  Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients. , 1997, Cancer research.

[25]  D. Hunt,et al.  Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100. , 1996, Journal of immunology.

[26]  P. van Endert,et al.  Characterization of antigenic peptides presented by HLA‐B44 molecules on tumor cells expressing the gene MAGE‐3 , 1996, International journal of cancer.

[27]  Philip J. R. Goulder,et al.  Phenotypic Analysis of Antigen-Specific T Lymphocytes , 1996, Science.

[28]  T. Springer,et al.  High endothelial venules (HEVs): specialized endothelium for lymphocyte migration. , 1995, Immunology today.

[29]  R. Gallo,et al.  Tumor antigen presentation by murine epidermal cells. , 1991, Journal of immunology.

[30]  A. Halpern,et al.  Model predicting survival in stage I melanoma based on tumor progression. , 1989, Journal of the National Cancer Institute.

[31]  J. Becker,et al.  Oligoclonal T-cell receptor usage of melanocyte differentiation antigen-reactive T cells in stage IV melanoma patients. , 2001, Cancer research.

[32]  C Caux,et al.  Immunobiology of dendritic cells. , 2000, Annual review of immunology.

[33]  R. Coleman,et al.  Migration of human dendritic cells after injection in patients with metastatic malignancies. , 1999, Cancer research.

[34]  J. Timmerman,et al.  Dendritic cell vaccines for cancer immunotherapy. , 1999, Annual review of medicine.